Will Availability of SMOF Lipid Emulsions for Parenteral Nutrition Change Surgical Nutrition Practice?

2017 ◽  
Vol 6 (3) ◽  
pp. 266-273
Author(s):  
Elizabeth H. Cameron ◽  
Neal Bhutiani ◽  
Matthew C. Bozeman
2019 ◽  
Author(s):  
Srinivas Bolisetty ◽  
David Osborn ◽  
Tim Schindler ◽  
John Sinn ◽  
Girish Deshpande ◽  
...  

Abstract The first consensus standardised neonatal parenteral nutrition formulations were implemented in many neonatal units in Australia in 2012. The current update involving 49 units from Australia, New Zealand, Singapore, Malaysia and India was conducted between September 2015 and December 2017 with the aim to review and update the 2012 formulations and guidelines. Methods: A systematic review of available evidence for each parenteral nutrient was undertaken and new standardised formulations and guidelines were developed. Results: Five existing preterm Amino acid-Dextrose formulations have been modified and two new concentrated Amino acid-Dextrose formulations added to optimise amino acid and nutrient intake according to gestation. Organic phosphate has replaced inorganic phosphate allowing for an increase in calcium and phosphate content, and acetate reduced. Lipid emulsions are unchanged, with both SMOFlipid and ClinOleic preparations included. The physicochemical compatibility and stability of all formulations have been tested and confirmed. Guidelines to standardise the parenteral nutrition clinical practice across facilities have also been developed. Conclusions: Formulations and guidelines to standardise parenteral nutrition practice across the Australasian region have the potential to improve nutrition and clinical outcomes of neonates. Standardisation can also result in cost savings, quality improvement and error minimisation in PN prescribing and ordering.


2004 ◽  
Vol 23 (6) ◽  
pp. 1418-1425 ◽  
Author(s):  
Jean-Marie Reimund ◽  
Yves Arondel ◽  
Francisca Joly ◽  
Bernard Messing ◽  
Bernard Duclos ◽  
...  

1986 ◽  
Vol 73 (10) ◽  
pp. 843-846 ◽  
Author(s):  
J. R. T. Monson ◽  
Carol W. Ramsden ◽  
J. MacFie ◽  
T. G. Brennan ◽  
P. J. Guillou

2017 ◽  
Vol 9 (1) ◽  
pp. 21-29
Author(s):  
Jeong-A Park ◽  
Ji-Eun Park ◽  
Min-Jae Jeong ◽  
Jae-Song Kim ◽  
Eun-Sun Son ◽  
...  

2020 ◽  
Vol 123 (12) ◽  
pp. 1365-1372 ◽  
Author(s):  
Josep M. Llop-Talaveron ◽  
Elisabet Leiva-Badosa ◽  
Ana Novak ◽  
Raúl Rigo-Bonnin ◽  
Josep R. Ticó-Grau ◽  
...  

AbstractVegetable lipid emulsions (LE) contain non-declared phytosterols (PS). We aimed to determine PS content depending on the brand and LE batch, and in adult hospitalised patients treated with parenteral nutrition (PN), to establish the association between plasma and administered PS. Part I was the LE study: totals and fractions of PS in three to four non-consecutive batches from six LE were analysed. Part II was the patient study: patients with at least 7 previous days of PN with 0·8 g/kg per d of an olive/soyabean (O/S) LE were randomised (day 0) 1:1 to O/S or 100 % fish oil (FO) at a dose of 0·4 g/kg per d for 7 d (day 7). Plasma PS, its fractions, total cholesterol on days 0 and 7, their clearance and their association with PS administered by LE were studied. In part I, LE study: differences were found in the total PS, their fractions and cholesterol among different LE brands and batches. Exclusive soyabean LE had the highest content of PS (422·36 (sd 130·46) μg/ml). In part II, patient study: nineteen patients were included. In the O/S group, PS levels were maintained (1·11 (sd 6·98) μg/ml) from day 0 to 7, while in the FO group, significant decreases were seen in total PS (−6·21 (sd 4·73) μg/ml) and their fractions, except for campesterol and stigmasterol. Plasma PS on day 7 were significantly associated with PS administered (R2 0·443). PS content in different LE brands had great variability. PS administered during PN resulted in accumulation and could be prevented with the exclusive administration of FO LE.


Marine Drugs ◽  
2019 ◽  
Vol 17 (5) ◽  
pp. 274 ◽  
Author(s):  
Philip C. Calder

Lipids used in intravenous nutrition support (i.e., parenteral nutrition) provide energy, building blocks, and essential fatty acids. These lipids are included as emulsions since they need to be soluble in an aqueous environment. Fish oil is a source of bioactive omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid). Lipid emulsions, including fish oil, have been used for parenteral nutrition for adult patients post-surgery (mainly gastrointestinal). This has been associated with alterations in biomarkers of inflammation and immune defense, and in some studies, a reduction in length of intensive care unit and hospital stay. These benefits, along with a reduction in infections, are emphasized through recent meta-analyses. Perioperative administration of fish oil may be superior to postoperative administration, but this requires further exploration. Parenteral fish oil has been used in critically ill adult patients. Here, the influence on inflammatory processes, immune function, and clinical endpoints is less clear. However, some studies found reduced inflammation, improved gas exchange, and shorter length of hospital stay in critically ill patients if they received fish oil. Meta-analyses do not present a consistent picture but are limited by the small number and size of studies. More and better trials are needed in patient groups in which parenteral nutrition is used and where fish oil, as a source of bioactive omega-3 fatty acids, may offer benefits.


Sign in / Sign up

Export Citation Format

Share Document